Orchestra BioMed Inc. (OBIO)
2.61
-0.24 (-8.42%)
At close: Apr 24, 2025, 1:34 PM
-8.42% (1D)
| Bid | 2.57 |
| Market Cap | 100M |
| Revenue (ttm) | 2.64M |
| Net Income (ttm) | -61.02M |
| EPS (ttm) | -1.64 |
| PE Ratio (ttm) | -1.59 |
| Forward PE | -1.66 |
| Analyst | Buy |
| Ask | 2.62 |
| Volume | 203,286 |
| Avg. Volume (20D) | 297,995 |
| Open | 2.78 |
| Previous Close | 2.85 |
| Day's Range | 2.52 - 2.79 |
| 52-Week Range | 2.49 - 8.87 |
| Beta | 0.62 |
About OBIO
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collabora...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 4, 2020
Employees 70
Stock Exchange NASDAQ
Ticker Symbol OBIO
Website https://orchestrabiomed.com
Analyst Forecast
According to 5 analyst ratings, the average rating for OBIO stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 474.71% from the latest price.
Stock ForecastsNext Earnings Release
Orchestra BioMed Inc. is scheduled to release its earnings on May 12, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
Orchestra BioMed shares are trading higher after t...
Unlock content with
Pro Subscription
3 weeks ago
Orchestra BioMed shares are trading lower after the company reported a FY24 sales miss.
